SELECT: Randomized phase III study of docetaxel (D) or pemetrexed (P) with or without cetuximab (C) in recurrent or progressive non-small cell lung cancer (NSCLC) after platinum-based therapy.
Edward S. Kim
Consultant or Advisory Role - Boehringer Ingelheim; Genentech; Lilly; OSI Pharmaceuticals
Research Funding - Genentech; Lilly; OSI Pharmaceuticals
Marcus A. Neubauer
Employment or Leadership Position - USON Med Director
Allen Lee Cohn
No relevant relationships to disclose
Lee Steven Schwartzberg
No relevant relationships to disclose
Lawrence E. Garbo
No relevant relationships to disclose
John Robert Caton
No relevant relationships to disclose
Francisco Robert
Research Funding - University of Alabama at Birmingham
Terry Katz
Employment or Leadership Position - ImClone Systems
Sreenivas Chittoor
No relevant relationships to disclose
Lorinda Simms
Employment or Leadership Position - Lilly
Stock Ownership - Lilly
Scott Saxman
Employment or Leadership Position - Lilly
Stock Ownership - Lilly